CytRx bear thesis explained: why sarcoma drug trial will fail dlvr.it/LGs5kh

$AGN authorizes $10 billion buy back, beats estimates dlvr.it/LGslpr

Cramer sees more upside in $AGN dlvr.it/LGxWSv

Global bidding war seen for Medivation dlvr.it/LHPJB9

DOJ investigation has little impact on pharmas' share prices dlvr.it/LHR5s7

Mast (mstx) sickle cell drug seeks to defy long odds like leicester city dlvr.it/LHmxLP

Cramer says buy $DOW & $DD over $MON in seed business dlvr.it/LHtcG3

New regime at $PRGO provides reason to invest dlvr.it/LHxJV8

Biotech Stock Mailbag: Why Intrexon CEO R.J. Kirk should not be trusted $XON dlvr.it/LJCHFD

$MYL tacks on another generics company on the cheap dlvr.it/LJKvns

$MDVN shares stand pat amid further bid speculation dlvr.it/LJR9kW

Pfizer Buying Anacor in $5.2 Billion Cash Deal dlvr.it/LKNMtF

Aduro Biotech Pancreatic Cancer Immunotherapy Fails Mid-Stage Study dlvr.it/LKS1fy

Pfizer beats Allergan to excema-drugmaker Anacor for $5.2B dlvr.it/LKTpTn

$REGN spike not tied to $PFE's $ANAC deal, but it doesn't hurt dlvr.it/LKYmNy

Investors comforted as Perrigo sticks to forecast dlvr.it/LKx9q0

Celgene, Agios Expand, Amend Cancer Drug Partnership dlvr.it/LL17gk

Heron and the never-ending FDA drug review dlvr.it/LLNbYj

Heron and the never-ending FDA drug review dlvr.it/LLRmZR

Celgene, Agios Expand, Amend Cancer Drug Partnership dlvr.it/LLSGFV